Table 1 Previously published reports of Infliximab for the treatment of IVIG resistant Kawasaki disease.

Weiss et al

[14]

1

3 years

(M)

Giant CAA

IVIG × 8

MP × 8

Pred PO

5 mg/kg × 3

Resolution of fever post Infliximab; no further progression of CAA

Oishi et al

[15]

1

1 month

(F)

CAA of RCA and LCA

IVIG × 3 (first two doses at 1 g/kg, 3^rd dose at 2 g/Kg)

MP × 2

Pred PO

Ulinastatin

5 mg/kg × 1

Defervesced within 24 hours of infliximab; developed transient urticaria post infliximab

Girish et al

[16]

1

4 years

(M)

CAA of RCA and LCA

IVIG × 2

MP × 3

5 mg/kg × 1

Immediate defervescence post infliximab

Burns et al

[18]

17

2.6 years (0.12–13.1);

(11 M/6F)

12/17

All received at least 2 doses of IVIG;

8/17 MP (1–3 doses)

5 mg/kg × 1 (15/17 patients); 10 mg/kg × 1 (2/17 patients)

13/16 febrile patients defervesced post infliximab; 1 patient died of cardiac arrest related to CAA 53 days after infliximab

Stenbog et al

[19]

2

11 weeks (M)

33 weeks (M)

2/2

Both received at least 2 doses of IVIG;

MP

Pred PO

6 mg/kg × 3

Prompt defervescence and regression of CAA in both cases

O'Connor et al

[20]

1

7 weeks

(M)

Giant CAA and peripheral gangrene

IVIG × 2

MP × 3

5 mg/kg × 2

Fever resolved after second dose of infliximab; patient received pred PO (for 2 weeks) after infliximab

Burns et al

[21]

16

1.7 years (0.7–3.1)

(8M/4F)

sex not documented in 4 patients receiving infliximab after 2 doses of IVIG

5/16

Single dose of IVIG (n = 12);

IVIG × 2 (n = 4)

5 mg/kg × 1

11/12 patients receiving infliximab after a single IVIG dose defervesced within 24 hours; 2/4 patients receiving infliximab after 2 doses of IVIG defervesced; no serious adverse events